1. Combining rapid diagnostic tests to estimate primary and post-primary dengue immune status at the point of care.
- Author
-
Biggs, Joseph R., Sy, Ava Kristy, Ashall, James, Santoso, Marsha S., Brady, Oliver J., Reyes, Mary Anne Joy, Quinones, Mary Ann, Jones-Warner, William, Tandoc, Amadou O., Sucaldito, Nemia L., Mai, Huynh Kim, Lien, Le Thuy, Thai, Hung Do, Nguyen, Hien Anh Thi, Anh, Dang Duc, Iwasaki, Chihiro, Kitamura, Noriko, Van Loock, Marnix, Herrera-Taracena, Guillermo, and Menten, Joris
- Subjects
DENGUE hemorrhagic fever ,IMMUNITY ,POINT-of-care testing ,DENGUE ,DIAGNOSIS methods ,DENGUE viruses - Abstract
Background: Characterising dengue virus (DENV) infection history at the point of care is challenging as it relies on intensive laboratory techniques. We investigated how combining different rapid diagnostic tests (RDTs) can be used to accurately determine the primary and post-primary DENV immune status of reporting patients during diagnosis. Methods and findings: Serum from cross-sectional surveys of acute suspected dengue patients in Indonesia (N:200) and Vietnam (N: 1,217) were assayed using dengue laboratory assays and RDTs. Using logistic regression modelling, we determined the probability of being DENV NS1, IgM and IgG RDT positive according to corresponding laboratory viremia, IgM and IgG ELISA metrics. Laboratory test thresholds for RDT positivity/negativity were calculated using Youden's J index and were utilized to estimate the RDT outcomes in patients from the Philippines, where only data for viremia, IgM and IgG were available (N:28,326). Lastly, the probabilities of being primary or post-primary according to every outcome using all RDTs, by day of fever, were calculated. Combining NS1, IgM and IgG RDTs captured 94.6% (52/55) and 95.4% (104/109) of laboratory-confirmed primary and post-primary DENV cases, respectively, during the first 5 days of fever. Laboratory test predicted, and actual, RDT outcomes had high agreement (79.5% (159/200)). Among patients from the Philippines, different combinations of estimated RDT outcomes were indicative of post-primary and primary immune status. Overall, IgG RDT positive results were confirmatory of post-primary infections. In contrast, IgG RDT negative results were suggestive of both primary and post-primary infections on days 1–2 of fever, yet were confirmatory of primary infections on days 3–5 of fever. Conclusion: We demonstrate how the primary and post-primary DENV immune status of reporting patients can be estimated at the point of care by combining NS1, IgM and IgG RDTs and considering the days since symptoms onset. This framework has the potential to strengthen surveillance operations and dengue prognosis, particularly in low resource settings. Author summary: Combined NS1, IgM and IgG dengue rapid diagnostic tests (RDTs) have previously been shown to accurately diagnose those experiencing dengue virus (DENV) infections at the point of care and are now available as single commercial kits. Using such kits to additionally determine those experiencing primary (first) or post-primary (second, third or fourth) dengue infections however remains challenging as accurate immune status classification currently relies on laboratory analysis. We used logistic regression modelling methods to estimate RDT positive and negative outcomes according to corresponding PCR and ELISA laboratory-based methods, which showed high sensitivity and specificity. Dengue RDT outcomes were then predicted among a large sample of suspected dengue case reports, to calculate the probability of being primary or post-primary for dengue according to every possible set of dengue RDT outcomes, by day of fever. Different RDT outcomes, at certain stages of infection, were indicative of primary and post-primary immune status. Using our framework to determine dengue immune status at the point of care in low resource settings, regional surveillance systems could estimate and monitor dengue transmission intensity. Additionally, this framework could potentially support dengue prognosis and identify primary cases who would benefit from current vaccination regimes to prevent subsequent secondary infections associated with severe disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF